Background: Covid-19 pandemic is causing a very high death toll around the world and
a severe fall in the global economy. Many clinical trials are currently underway to check the effectiveness
of some known drugs. The physiopathology associated with the virus infection is currently
better understood and good prophylactic drug therapies are implemented, such as antibiotics and
blood thinners, though, no specific drugs against SARS-Cov-2 were developed yet.
Objective: In the present research work, it is aimed to carry out a bibliographic investigation on
some active molecular species that could be used against Covid-19, based on their chemical properties
to bind to glycoproteins. In the case of SARS-Cov-2, the targeted glycoprotein is the surface
virus spike S glycoprotein, that the virus uses to attach to and invade human cells. It is of high pharmacological
value to investigate possible active natural substances endowed with a property to
bind glycoproteins. In this line of research, oligosaccharides and lectins are two molecular species
that have glycoprotein binding properties.
Methods: A bibliographic research was carried out on oligosaccharides and lectins in various
sources of scientific publications. Relevant chemical and pharmacological properties of oligosaccharides
and lectins were searched and their main natural sources were identified.
Results: In the present paper, I summarize some scientific evidence to support the therapeutic potential
of camel milk as a source of oligosaccharides and its possible use as a functional diet in parallel
to drug therapies of Covid-19. On the other hand, sugar and glycoprotein binding properties of
some lectins of plant and seaweed origin are reported, and their pharmaceutical use is underlined.
Conclusion: In the present study, scientific evidence was documented that encouraged further clinical
investigations on camel milk oligosaccharides and lectins of plant and seaweed origin in the management
of Covid-19 physiopathology.